NSAID exacerbated respiratory disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:28:16 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png NSAID exacerbated respiratory disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Aspirin’s Role in Reducing COVID-19 Risk for Patients with Aspirin-Exacerbated Respiratory Disease https://clinicaltrials.eu/trial/study-on-aspirins-role-in-reducing-covid-19-risk-for-patients-with-aspirin-exacerbated-respiratory-disease/ Wed, 29 Apr 2026 15:05:35 +0000 https://clinicaltrials.eu/trial/study-on-aspirins-role-in-reducing-covid-19-risk-for-patients-with-aspirin-exacerbated-respiratory-disease/ This clinical trial is focused on studying a condition known as aspirin-exacerbated respiratory disease (AERD). AERD is a respiratory condition that can worsen with the use of aspirin. The study is investigating whether long-term use of aspirin, specifically a 300 mg tablet form known as ACARD, can reduce the risk of infection with the SARS-CoV-2 virus, which causes COVID-19, in patients with AERD.

The purpose of the study is to see if aspirin, which works by blocking a specific enzyme in the body, can help predict a lower chance of getting infected with the virus. The study will also look at certain genetic features that might influence how the body responds to the virus when taking high doses of aspirin. Participants will be given either aspirin or a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, researchers will monitor changes in specific genes that might be linked to a reduced risk of SARS-CoV-2 infection. The study will last for a period of time, during which participants will take the medication and have regular check-ups to assess their health and any changes in their condition. The goal is to better understand how aspirin might help in managing the risk of COVID-19 in people with AERD.

]]> Study of intranasal lysine-aspirin effectiveness in patients with NSAID-exacerbated respiratory disease (N-ERD) https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-intranasal-lysine-aspirin-for-patients-with-nsaid-exacerbated-respiratory-disease/ Wed, 29 Apr 2026 15:05:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-intranasal-lysine-aspirin-for-patients-with-nsaid-exacerbated-respiratory-disease/ This study focuses on Nonsteroidal Anti-inflammatory Drug Exacerbated Respiratory Disease (N-ERD), a condition where patients experience breathing difficulties and increased sensitivity to certain pain medications. The study will evaluate the effectiveness of nasal lysine-aspirin, a modified form of aspirin, in managing symptoms of this condition.

The purpose of the study is to determine how well nasal lysine-aspirin helps control symptoms and improve quality of life for people with N-ERD. The study will use acetylsalicylic acid (aspirin) and sodium chloride solution as part of the treatment. Participants will receive the medication through the nose over a period of 49 days.

During the study, researchers will track changes in breathing problems, nasal congestion, sense of smell, and overall quality of life. They will also monitor how well asthma symptoms are controlled and any stomach-related side effects that may occur. The treatment involves gradually increasing the medication dose while carefully observing how participants respond to the treatment.

]]> Study on the Long-term Effects of Dupilumab for Patients with Aspirin-Exacerbated Respiratory Disease (AERD) https://clinicaltrials.eu/trial/study-on-the-long-term-effects-of-dupilumab-for-patients-with-aspirin-exacerbated-respiratory-disease-aerd/ Wed, 29 Apr 2026 15:05:00 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-effects-of-dupilumab-for-patients-with-aspirin-exacerbated-respiratory-disease-aerd/ This clinical trial is focused on studying the effects of a medication called Dupilumab on a condition known as non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). N-ERD is a type of respiratory disease that worsens when patients take certain pain relievers, like aspirin. The medication being tested, Dupilumab, is given as a solution for injection using a pre-filled syringe.

The purpose of this study is to understand how Dupilumab affects patients with N-ERD, particularly in terms of their tolerance to aspirin. The study aims to see if patients can tolerate higher doses of aspirin after being treated with Dupilumab for a long period. Participants will receive Dupilumab through subcutaneous injection, which means the medication is injected under the skin. The study will observe changes in aspirin tolerance before treatment, during treatment, and six months after starting the treatment.

Throughout the study, various health indicators will be monitored, such as levels of certain proteins and cells in the blood, as well as the presence of specific substances in nasal secretions and urine. The study will also assess changes in the sense of smell and the composition of bacteria in the nose. These observations will help researchers understand the broader effects of Dupilumab on the body and its potential benefits for patients with N-ERD.

]]>